Skip to main content

Table 1 Characteristics of included studies

From: Liposomal bupivacaine administration is not superior to traditional periarticular injection for postoperative pain management following total knee arthroplasty: a meta-analysis of randomized controlled trials

Study (year)

Setting

LB/TPAI

AN

Treatment group

Control group

Follow-up

PA

No.

Age

Male

Female

BMI

Bramlett 2012 [23]

USA

25/34

61.1/62.2

13/11

12/23

31.2/31.5

GA

LB 266 mg

Bup 150 mg

36 days

Y

Schroer 2015 [24]

USA

58/53

67/68.6

24/21

34/32

32/32

SA/GA

LB 266 mg, Bup 75 mg

Bup 150 mg

3 weeks

Y

Collis 2016 [25]

USA

54/51

63.7/63.5

25/14

29/37

34.1/35.7

GA

LB 266 mg

Rop 246.25 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg

8 weeks

N

Jain 2016 [26]

USA

63/62

68.3/67.5

19/17

44/45

33.3/33.3

SA

LB 266 mg

Bup 75 mg, Epi 0.15 mg, Mor 10 mg

NM

Y

Schwarzkopf 2016 [27]

USA

20/18

63/59

7/10

13/8

29.3/29.5

SA

LB 266 mg, Bup 50 mg

Rop 246.25 mg, Epi 0.5 mg, Clo 80 mg, Tor 30 mg

NM

Y

Snyder 2016 [28]

USA

35/35

67.3/65.6

22/15

13/20

30.68/31.29

SA/GA

LB 266 mg

Rop 400 mg, Epi 0.6 mg, Ket 30 mg, Mor 5 mg

10 days

N

Alijanipour 2017 [29]

USA

59/59

64.3/64.9

29/27

30/32

32.3/28.7

SA

LB 266 mg, Epi 0.5 mg

Bup 50 mg, Epi 0.1 mg

6 weeks

Y

Declaire 2017 [30]

USA

47/49

69.7/67.7

21/21

26/28

31.5/31.9

SA/GA

LB 266 mg, Bup, Epi, Ket, Mor

Rop, Epi, Ket, Mor

NM

Y

Mont 2017 [15]

USA

70/69

66/66

27/30

43/39

32.4/31.3

SA

LB 266 mg, Bup 100 mg

Bup 100 mg

NM

Y

Smith 2017 [31]

USA

104/96

66/66

54/28

50/68

31.5/31.6

SA

LB 266 mg

Bup

6 weeks

N

Danoff 2018 [32]

USA

29/29

62.9/62.9

15/15

14/14

30.4/30.4

SA

LB 266 mg, Bup 75 mg

Rop 250 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg

6 weeks

Y

Schumer 2018 [36]

USA

66/64

NM

NM

NM

NM

SA

LB 266 mg, Bup 1 mg/kg

Bup 150 mg

6 weeks

N

Suarez 2018 [33]

USA

52/52

68.1/67.3

19/26

33/26

30.8/32.01

SA

LB 266 mg, Bup 75 mg

Rop 246.25 mg, Epi 0.5 mg, Ket 30 mg, Clo 0.08 mg

6 weeks

Y

Zlotnicki 2018 [34]

USA

38/40

63.2/64.3

19/14

19/26

35.5/35.4

SA/GA

LB 266 mg

Bup 100 mg

NM

N

Dysart 2019 [35]

USA

70/69

66/66

29/28

41/41

NM

SA

LB 266 mg, Bup 100 mg

Bup 100 mg

24 h

N

Hyland 2019 [19]

USA

30/29

65.0/61.2

14/13

16/16

NM

GA + ACB

LB 266 mg

Rop 40 mg, Ket 30 mg, Mor 10 mg, Methy 40 mg

NM

Y

  1. G1, treatment group; G2, control group; AN, anesthesia; SA, spinal anesthesia, GA, general anesthesia; ACB, adductor canal nerve block; PA, power analysis; Bup, bupivacaine; Rop, ropivacaine; Epi, epinephrine; Ket, ketorolac; Mor, morphine; Methy, methylprednisolone acetate; Clo, clonidine, Tor, toradol